Drug Trial Radar · NCT06726096
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
615
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Apr 20, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Beijing VDJBio Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the treatment of moderate-to-severe active rheumatoid arthritis with poor response to methotrexate
Conditions
- Rheumatoid Arthritis (RA)
- Anti IL-6R
Interventions
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody InjectionBiological
The drug was administered once every 4 weeks. Other Names: Tocilizumab Injection placebo control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving ACR50 at week 24 (W24).Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.